LU92389I2 - Cystéamine - Google Patents

Cystéamine Download PDF

Info

Publication number: LU92389I2
Authority: LU; Luxembourg
Prior art keywords: cysteamine
Prior art date: 2006-01-27

Application number

LU92389C

Other languages

English (en)

French (fr)

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-27

Filing date

2014-03-05

Publication date

2015-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38327943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92389(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-05 Application filed by Univ California filed Critical Univ California

2015-10-29 Publication of LU92389I2 publication Critical patent/LU92389I2/xx

Links

UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 title 1
229960003151 mercaptamine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2873—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Botany (AREA)
Psychology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Toxicology (AREA)
Obesity (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

LU92389C 2006-01-27 2014-03-05 Cystéamine LU92389I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US76271506P	2006-01-27	2006-01-27
PCT/US2007/002325 WO2007089670A2 (en)	2006-01-27	2007-01-26	Enterically coated cysteamine, cystamine and derivatives thereof

Publications (1)

Publication Number	Publication Date
LU92389I2 true LU92389I2 (fr)	2015-10-29

Family

ID=38327943

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92389C LU92389I2 (fr)	2006-01-27	2014-03-05	Cystéamine

Country Status (20)

Country	Link
US (15)	US8026284B2 (pl)
EP (3)	EP3659588A1 (pl)
AU (1)	AU2007210005C1 (pl)
BR (1)	BRPI0707277B1 (pl)
CA (1)	CA2640531C (pl)
CY (1)	CY1122943T1 (pl)
DK (2)	DK2535044T3 (pl)
EA (2)	EA023971B1 (pl)
ES (2)	ES2774755T3 (pl)
FR (1)	FR14C0018I1 (pl)
HU (1)	HUE049307T2 (pl)
IL (1)	IL193044A (pl)
LT (1)	LT2535044T (pl)
LU (1)	LU92389I2 (pl)
MX (2)	MX2008009647A (pl)
NL (1)	NL300649I2 (pl)
PL (2)	PL2535044T3 (pl)
PT (2)	PT2535044T (pl)
SI (2)	SI1919458T1 (pl)
WO (1)	WO2007089670A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007089670A2 (en)	2006-01-27	2007-08-09	The Regents Of The University Of California	Enterically coated cysteamine, cystamine and derivatives thereof
WO2009070781A1 (en) *	2007-11-30	2009-06-04	The Regents Of The University Of California	Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
WO2011011733A2 (en) *	2009-07-24	2011-01-27	The Regents Of The University Of Michigan	Factor replacement therapy
US8815942B2 (en)	2010-10-20	2014-08-26	The Royal Institution For The Advancement Of Learning/Mcgill University	Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
CA2732440C (en) *	2011-02-23	2017-10-31	Universite Laval	Cystamine analogues for the treatment of parkinson`s disease
US9468612B2 (en)	2011-10-26	2016-10-18	Seattle Children's Hospital	Cysteamine in the treatment of fibrotic disease
US20140314841A1 (en) *	2013-04-19	2014-10-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv	Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
TWI659209B (zh) *	2013-06-17	2019-05-11	地平線罕見醫學製藥有限責任公司	分析半胱胺組合物的方法
TWI649100B (zh) *	2013-06-17	2019-02-01	地平線罕見醫學製藥有限責任公司	延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
WO2015175886A1 (en) *	2014-05-16	2015-11-19	Children's Hospital Medical Center	Methods for assessing responsiveness to asthma treatment based on vnn-1 expression and promoter methylation
TW201618760A (zh) *	2014-11-05	2016-06-01	雷普特製藥有限公司	使用半胱胺組合物治療亨廷頓氏病之方法
RU2766579C2 (ru)	2015-07-02	2022-03-15	ХОРАЙЗОН ОРФАН ЭлЭлСи	Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
WO2017087532A1 (en)	2015-11-16	2017-05-26	The Regents Of The University Of California	Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en)	2015-11-17	2018-12-04	Horizon Orphan Llc	Methods for storing cysteamine formulations and related methods of treatment
MX392606B (es)	2016-03-17	2025-03-24	Thiogenesis Therapeutics Inc	Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
ITUA20161799A1 (it)	2016-03-18	2017-09-18	Recordati Ind Chimica E Farmaceutica S P A	Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3308773A1 (en)	2016-10-11	2018-04-18	Recordati Industria Chimica E Farmaceutica SPA	Formulations of cysteamine and cysteamine derivatives
WO2018093364A1 (en) *	2016-11-16	2018-05-24	The Regents Of The University Of California	Formulations of cysteamine and cystamine
US10251850B2 (en)	2017-01-11	2019-04-09	Lupin Limited	Process for preparation of cysteamine bitartrate
WO2019060634A1 (en)	2017-09-20	2019-03-28	Thiogenesis Therapeutics, Inc.	METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS
US20200253867A1 (en)	2017-09-22	2020-08-13	University Of Florida Research Foundation	Devices and methods for reducing cystine crystals in vivo
GB2581362A (en)	2019-02-14	2020-08-19	Univ Of Sunderland	Chemical synthesis
WO2020198529A1 (en)	2019-03-26	2020-10-01	The Regents Of The University Ofcalifornia	Substituted amino-thiol and amino-disulfide compounds, and uses thereof
EP3959499B1 (en) *	2019-04-25	2025-02-19	Fremonta Corporation	Powered sampling device and method
US20240009148A1 (en) *	2020-11-19	2024-01-11	Birch Therapeutics, Inc.	Cystamine Formulations and Uses Thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2809918A (en)	1955-10-17	1957-10-15	Victor M Hermelin	Sustained release pharmaceutical preparations
DE2010416B2 (de)	1970-03-05	1979-03-29	Hoechst Ag, 6000 Frankfurt	Oral anwendbare Arzneiform mit Retardwirkung
US4110441A (en)	1974-04-29	1978-08-29	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.	Gamma-l-glutamyl cholamine phosphate
FR2471186A1 (fr)	1979-12-10	1981-06-19	Roussel Uclaf	Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en)	1980-07-29	1981-11-17	G. D. Searle & Co.	Stabilization of 16-oxygenated prostanoic acid derivatives
US4728512A (en)	1985-05-06	1988-03-01	American Home Products Corporation	Formulations providing three distinct releases
US4794001A (en)	1986-03-04	1988-12-27	American Home Products Corporation	Formulations providing three distinct releases
US4959306A (en)	1986-11-28	1990-09-25	Sclavo, Inc.	Labeling design for a binding assay reagent
US5668117A (en) *	1991-02-22	1997-09-16	Shapiro; Howard K.	Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5225202A (en)	1991-09-30	1993-07-06	E. R. Squibb & Sons, Inc.	Enteric coated pharmaceutical compositions
US5639743A (en) *	1992-11-13	1997-06-17	University Of Georgia Research Foundation	Compositions and methods for treating exocrine gland atrophy
CA2236344A1 (en) *	1998-04-30	1999-10-30	Hemosol Inc.	Hemoglobin-haptoglobin complexes
UA69413C2 (uk)	1998-05-22	2004-09-15	Брістол-Майерс Сквібб Компані	Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US6794414B1 (en)	1998-06-17	2004-09-21	Yeda Research And Development Co. Ltd.	Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) *	1998-07-17	2005-06-15	Брістол-Майерс Сквібб Компані	Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20030137125A1 (en)	2000-02-14	2003-07-24	Len Booysen	Stabilizer unit
CN1144585C (zh)	2000-12-13	2004-04-07	华扩达动物科学[I.P.2]有限公司	含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US20050004075A1 (en)	2000-12-13	2005-01-06	Walcom Animal Science (I.P.2) Limited	Composition for regulating animal growth, method of manufacture and use thereof
GB2377874B (en)	2001-07-23	2005-06-22	Walcom Bio Chemicals Ind Ltd	Poultry feed and the use thereof
US7449451B2 (en) *	2001-08-29	2008-11-11	Premier Micronutrient Corporation	Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en)	2001-09-19	2006-04-19	Walcom Animal Science	Dairy cow feed and the use thereof
US20030157191A1 (en)	2001-11-29	2003-08-21	Sound Pharmaceuticals Incorporated	Methods and compositions for ameliorating the undesirable effects of chemotherapy
DK1471902T3 (da)	2002-01-04	2014-09-08	Sound Pharmaceuticals Inc	Sammensætninger til brug i fremgangsmåder til behandling af høretab
GB2386817B (en) *	2002-02-20	2006-08-23	Walcom Animal Science	Feed for fish and use therof
US8017651B2 (en)	2002-11-22	2011-09-13	Bionexus, Ltd.	Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en)	2003-02-19	2004-08-25	Walcom Animal Science	Composition for improving immunity of animals
US8029822B2 (en) *	2003-05-22	2011-10-04	Osmotica Kereskedelmi és Seolgáltató KFT	Rupturing controlled release device having a preformed passageway
WO2005049002A1 (en)	2003-11-19	2005-06-02	Omega Bio-Pharma International Ltd.	Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers
TWI350751B (en)	2003-12-19	2011-10-21	Omega Bio Pharma Ip3 Ltd	Pharmaceutical compositions for treating diabetes
US20050209441A1 (en)	2004-03-22	2005-09-22	Lile Jackson D	Process for promoting proper folding of human serum albumin using a human serum albumin ligand
AU2005240122B2 (en)	2004-05-03	2011-02-17	Omega Bio-Pharma (I.P.3) Limited	Cysteamines for treating complications of hypercholesterolemia and diabetes
PT1879599E (pt)	2005-04-20	2014-01-23	Hutchinson Fred Cancer Res	Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos
AR057623A1 (es)	2005-11-28	2007-12-05	Omega Bio Pharma H K Ltd	Materiales y metodos para el tratamiento de las infecciones virales
KR101394245B1 (ko)	2005-12-30	2014-05-14	에스케이바이오팜 주식회사	아이속사졸 유도체 및 이의 용도
US20070172514A1 (en)	2006-01-20	2007-07-26	Francis Chi	Materials and methods for improving livestock productivity
WO2007089670A2 (en)	2006-01-27	2007-08-09	The Regents Of The University Of California	Enterically coated cysteamine, cystamine and derivatives thereof
WO2009070781A1 (en)	2007-11-30	2009-06-04	The Regents Of The University Of California	Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
US20090209650A1 (en)	2008-02-17	2009-08-20	Francis Chi	Materials and Methods for Improving the health of Shrimp

2007
- 2007-01-26 WO PCT/US2007/002325 patent/WO2007089670A2/en not_active Ceased
- 2007-01-26 CA CA2640531A patent/CA2640531C/en active Active
- 2007-01-26 EP EP19206788.2A patent/EP3659588A1/en active Pending
- 2007-01-26 US US11/990,869 patent/US8026284B2/en active Active
- 2007-01-26 PT PT121698666T patent/PT2535044T/pt unknown
- 2007-01-26 AU AU2007210005A patent/AU2007210005C1/en active Active
- 2007-01-26 DK DK12169866.6T patent/DK2535044T3/da active
- 2007-01-26 EP EP07762690.1A patent/EP1919458B3/en active Active
- 2007-01-26 LT LTEP12169866.6T patent/LT2535044T/lt unknown
- 2007-01-26 ES ES12169866T patent/ES2774755T3/es active Active
- 2007-01-26 BR BRPI0707277-5A patent/BRPI0707277B1/pt active IP Right Grant
- 2007-01-26 PT PT07762690T patent/PT1919458E/pt unknown
- 2007-01-26 MX MX2008009647A patent/MX2008009647A/es active IP Right Grant
- 2007-01-26 PL PL12169866T patent/PL2535044T3/pl unknown
- 2007-01-26 SI SI200731035T patent/SI1919458T1/sl unknown
- 2007-01-26 SI SI200732147T patent/SI2535044T1/sl unknown
- 2007-01-26 ES ES07762690.1T patent/ES2388310T7/es active Active
- 2007-01-26 PL PL07762690T patent/PL1919458T6/pl unknown
- 2007-01-26 EA EA200801752A patent/EA023971B1/ru not_active IP Right Cessation
- 2007-01-26 EP EP12169866.6A patent/EP2535044B1/en not_active Revoked
- 2007-01-26 MX MX2015013747A patent/MX382184B/es unknown
- 2007-01-26 EA EA201600089A patent/EA201600089A1/ru unknown
- 2007-01-26 HU HUE12169866A patent/HUE049307T2/hu unknown
- 2007-01-26 DK DK07762690.1T patent/DK1919458T6/en active
2008
- 2008-07-24 IL IL193044A patent/IL193044A/en active IP Right Grant
2011
- 2011-07-25 US US13/190,396 patent/US8129433B2/en not_active Expired - Fee Related
2012
- 2012-02-17 US US13/399,900 patent/US20120237599A1/en not_active Abandoned
2014
- 2014-03-05 LU LU92389C patent/LU92389I2/xx unknown
- 2014-03-05 NL NL300649C patent/NL300649I2/nl unknown
- 2014-03-05 FR FR14C0018C patent/FR14C0018I1/fr active Active
- 2014-11-28 US US14/555,993 patent/US20150283100A1/en not_active Abandoned
2015
- 2015-06-26 US US14/752,383 patent/US9198882B2/en active Active
- 2015-06-26 US US14/752,499 patent/US9192590B2/en active Active
- 2015-11-24 US US14/950,234 patent/US9511039B2/en active Active
2016
- 2016-07-27 US US15/220,693 patent/US9750708B2/en active Active
- 2016-07-29 US US15/224,414 patent/US9795578B2/en active Active
- 2016-10-27 US US15/336,405 patent/US9814689B2/en active Active
2017
- 2017-07-21 US US15/656,884 patent/US9925157B2/en active Active
- 2017-07-21 US US15/656,863 patent/US9925156B2/en active Active
- 2017-07-21 US US15/656,903 patent/US9925158B2/en active Active
2018
- 2018-03-15 US US15/922,520 patent/US10485774B2/en active Active
2019
- 2019-11-14 US US16/684,000 patent/US11311507B2/en active Active
2020
- 2020-03-16 CY CY20201100240T patent/CY1122943T1/el unknown

Also Published As

Publication number	Publication date
CA2640531C (en)	2017-01-03
US10485774B2 (en)	2019-11-26
US20170319522A1 (en)	2017-11-09
MX382184B (es)	2025-03-13
PL1919458T6 (pl)	2017-10-31
US8026284B2 (en)	2011-09-27
PL2535044T3 (pl)	2020-06-29
LT2535044T (lt)	2020-04-10
US20160151310A1 (en)	2016-06-02
IL193044A (en)	2016-04-21
WO2007089670A2 (en)	2007-08-09
US20150290149A1 (en)	2015-10-15
US20120237599A1 (en)	2012-09-20
US9198882B2 (en)	2015-12-01
US9511039B2 (en)	2016-12-06
DK2535044T3 (da)	2020-03-23
US20170319524A1 (en)	2017-11-09
EP1919458A2 (en)	2008-05-14
EP1919458A4 (en)	2010-05-26
EA201600089A1 (ru)	2017-01-30
US20150283100A1 (en)	2015-10-08
US20150290150A1 (en)	2015-10-15
IL193044A0 (en)	2009-02-11
US8129433B2 (en)	2012-03-06
US20160331691A1 (en)	2016-11-17
HUE049307T2 (hu)	2020-09-28
CA2640531A1 (en)	2007-08-09
AU2007210005B2 (en)	2013-09-05
DK1919458T3 (da)	2012-08-20
EP2535044A1 (en)	2012-12-19
US20120015038A1 (en)	2012-01-19
DK1919458T6 (en)	2017-03-27
AU2007210005C1 (en)	2014-01-23
ES2388310T7 (es)	2017-05-03
US20170042845A1 (en)	2017-02-16
US9192590B2 (en)	2015-11-24
WO2007089670A3 (en)	2007-11-29
EP3659588A1 (en)	2020-06-03
US20160331705A1 (en)	2016-11-17
US20190060264A1 (en)	2019-02-28
US9925157B2 (en)	2018-03-27
US9925156B2 (en)	2018-03-27
US20090076166A1 (en)	2009-03-19
US9795578B2 (en)	2017-10-24
NL300649I2 (pl)	2017-01-03
PT1919458E (pt)	2012-08-23
DK1919458T5 (en)	2014-03-17
PL1919458T3 (pl)	2012-12-31
EP2535044B1 (en)	2019-12-18
US20200338033A1 (en)	2020-10-29
EA023971B1 (ru)	2016-08-31
BRPI0707277A2 (pt)	2011-04-26
US11311507B2 (en)	2022-04-26
BRPI0707277B1 (pt)	2021-07-13
EA200801752A1 (ru)	2008-12-30
EP1919458B3 (en)	2017-01-11
FR14C0018I1 (fr)	2014-04-11
SI2535044T1 (sl)	2020-06-30
CY1122943T1 (el)	2021-10-29
ES2388310T3 (es)	2012-10-11
EP1919458B1 (en)	2012-07-11
SI1919458T1 (sl)	2012-11-30
US9925158B2 (en)	2018-03-27
AU2007210005A1 (en)	2007-08-09
ES2774755T3 (es)	2020-07-22
US9750708B2 (en)	2017-09-05
US20170319523A1 (en)	2017-11-09
US9814689B2 (en)	2017-11-14
PT2535044T (pt)	2020-03-26
MX2008009647A (es)	2008-09-25

Publication	Publication Date	Title
DK2096917T3 (da)	2014-09-15	Cyclopamin-analoger
DK2081937T3 (da)	2012-10-01	Triazolopyridazin-proteinkinasemodulatorer
DE602006004717D1 (de)	2009-02-26	Kapselperforationsmodul
DE602007002544D1 (de)	2009-11-05	Nuancierungsmittel
EP1984575A4 (en)	2014-04-02	Wear assembly
DE602007013937D1 (de)	2011-05-26	Torantagonisten
DE602007009650D1 (de)	2010-11-18	Spiroindolinonderivate
EP1996173A4 (en)	2012-02-29	Powder filling processes
DE602007003893D1 (de)	2010-02-04	Kippambossanordnung
AT504580A3 (de)	2008-07-15	Scan-einrichtung
DE602007006947D1 (de)	2010-07-15	Pyridopyrimidinonderivate
DE602007000258D1 (de)	2009-01-02	Kassetteneinspannmechanismus
DE602007009337D1 (de)	2010-11-04	Tastfeedbackvorrichtung
DE602007001280D1 (de)	2009-07-30	Getränkeextraktor
DK1984239T3 (da)	2013-12-02	Dobbeltlags-tørdragt
DE602007001098D1 (de)	2009-06-25	Spindelmäheinheit
DE602006020192D1 (de)	2011-03-31	Riemenscheibenanorndung
DE602007008400D1 (de)	2010-09-23	Kaliummonopersulfatlösungen
DE602007010359D1 (de)	2010-12-16	Azaspiroderivate
DE502007001629D1 (de)	2009-11-12	Rfahren
BRPI0717939A2 (pt)	2013-12-03	Aminometil-4-imidazóis
DE602007000501D1 (de)	2009-03-12	Breitbandrichtkoppler
DE502007002453D1 (de)	2010-02-11	Kunstoffverdichtergehäuse
DE602007010544D1 (de)	2010-12-30	Motorstatorstruktur
DE602007004080D1 (de)	2010-02-11	Tintenstrahlaufnehmer